ReviewElectrolyte & blood pressure : E & BP2026
The Role of Extracellular Vesicles in the Pathogenesis of Hypertension.
Review in Electrolyte & blood pressure : E & BP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is one of the most common health problems and a leading global risk factor for cardiovascular, cerebrovascular, and renal diseases. The pathogenesis of essential hypertension is complex, and many organs, such as the heart, kidneys, arteries, and immune system, are involved in its pathophysiology. Extracellular vesicles (EVs) are membrane-bound nanosized structures that are generated and released into the extracellular fluid by all cell types. They mediate cell-to-cell communication in various physiological and pathophysiological processes. Therefore, EVs may play pivotal roles in the pathogenesis and systemic progression of diverse pathological conditions, including inflammatory, vascular, neoplastic, infectious, and neurodegenerative disorders. Emerging evidence has underscored their involvement in the development and progression of hypertension. Circulating and urinary EVs are promising diagnostic, prognostic, and therapeutic biomarkers of cardiovascular diseases, including hypertension. Moreover, EV-mediated therapies, particularly engineered EVs designed for precise drug delivery, are currently being developed for the treatment of various cardiovascular disorders, including hypertension and myocardial infarction. This review explores the role of EVs in the pathogenesis of hypertension and summarizes their potential as diagnostic and prognostic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.